Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biopharmaceutical company based in Sarasota, Florida, dedicated to the discovery and development of a novel class of anti-infective agents. The company's proprietary technology platform, known as Bisphosphocins™, consists of synthetic, small-molecule compounds designed to address the growing global threat of multi-drug resistant (MDR) bacterial, viral, and fungal infections. Unlike traditional antibiotics that often target specific metabolic pathways, Bisphosphocins utilize a unique mechanism of action that rapidly disrupts the bacterial cell membrane. This physical mode of action makes it significantly more difficult for pathogens to develop resistance, offering a potential breakthrough for patients who have exhausted conventional treatment options. The company's lead product candidate, Nu-3, is being developed as a topical and systemic antimicrobial. It has been studied for the treatment of infected diabetic foot ulcers and other chronic wounds where biofilm and resistant bacteria are prevalent. Beyond wound care, Lakewood-Amedex is exploring the application of its platform for respiratory tract infections and other systemic indications. The company aims to leverage its intellectual property and clinical data to form strategic partnerships and advance its pipeline through the regulatory approval process to meet the urgent need for effective new anti-infectives.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!